Search Results - "N. van Grieken"

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Obermannová, R., Alsina, M., Cervantes, A., Leong, T., Lordick, F., Nilsson, M., van Grieken, N.C.T., Vogel, A., Smyth, E.C.

“…•This ESMO Clinical Practice Guideline provides key recommendations for managing oesophageal cancer.•The guideline covers clinical and pathological diagnosis,…”
Get full text

MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma by van Velzen, M.J.M., Derks, S., van Grieken, N.C.T., Haj Mohammad, N., van Laarhoven, H.W.M.

“…•MSI-H has been associated with favorable survival outcomes in gastroesophageal cancer.•In gastroesophageal cancer, MSI-H tumors show resistance to specific…”
Get full text

Early outcomes from the Dutch Upper Gastrointestinal Cancer Audit by Busweiler, L. A. D., Wijnhoven, B. P. L., van Berge Henegouwen, M. I., Henneman, D., van Grieken, N. C. T., Wouters, M. W. J. M., van Hillegersberg, R., van Sandick, J. W.

“…Background In 2011, the Dutch Upper Gastrointestinal Cancer Audit (DUCA) group began nationwide registration of all patients undergoing surgery with the…”
Get full text

Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial by de Steur, W.O., van Amelsfoort, R.M., Hartgrink, H.H., Putter, H., Meershoek-Klein Kranenbarg, E., van Grieken, N.C.T., van Sandick, J.W., Claassen, Y.H.M., Braak, J.P.B.M., Jansen, E.P.M., Sikorska, K., van Tinteren, H., Walraven, I., Lind, P., Nordsmark, M., van Berge Henegouwen, M.I., van Laarhoven, H.W.M., Cats, A., Verheij, M., van de Velde, C.J.H.

“…The Intergroup 0116 and the MAGIC trials changed clinical practice for resectable gastric cancer in the Western world. In these trials, overall survival…”
Get full text

[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer by van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C. T., Dekker, H., van Dongen, G. A. M. S., Vugts, D. J., Boellaard, R., van Herpen, C. M. L., de Vries, E. G. E., Oyen, W. J. G., Brouwers, A. H., Verheul, H. M. W., Hoekstra, O. S., Menke-van der Houven van Oordt, C. W.

“…Purpose One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics…”
Get full text

Association between hospital volume and quality of gastric cancer surgery in the CRITICS trial by Claassen, Y. H. M., van Sandick, J. W., Hartgrink, H. H., Dikken, J. L., De Steur, W. O., van Grieken, N. C. T., Boot, H., Cats, A., Trip, A. K., Jansen, E. P. M., Meershoek‐Klein Kranenbarg, W. M., Braak, J. P. B. M., Putter, H., van Berge Henegouwen, M. I., Verheij, M., van de Velde, C. J. H.

“…Background Studies investigating the association between hospital volume and quality of gastric cancer surgery are lacking. In the present study, the effect of…”
Get full text

Effect of preoperative chemotherapy on the histopathological classification of gastric cancer by Caspers, I. A., Biesma, H. D., Wiklund, K., Pontén, F., Lind, P., Nordsmark, M., Sikorska, K., Meershoek-KleinKranenbarg, E., Hartgrink, H. H., van de Velde, C. J. H., van Sandick, J. W., Verheij, M., Cats, A., van Grieken, N. C. T.

“…Background In the era of individualized gastric cancer (GC) treatment, accurate determination of histological subtype becomes increasingly relevant. As yet, it…”
Get full text

KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study by van Grieken, N C T, Aoyma, T, Chambers, P A, Bottomley, D, Ward, L C, Inam, I, Buffart, T E, Das, K, Lim, T, Pang, B, Zhang, S L, Tan, I B, Carvalho, B, Heideman, D A M, Miyagi, Y, Kameda, Y, Arai, T, Meijer, G A, Tsuburaya, A, Tan, P, Yoshikawa, T, Grabsch, H I

“…Background: Inhibitors of the epidermal growth factor (EGFR) signaling pathway have a major role in the treatment of KRAS wild-type colorectal cancer patients…”
Get full text

Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers by de Cuba, E.M.V., Snaebjornsson, P., Heideman, D.A.M., van Grieken, N.C.T., Bosch, L.J.W., Fijneman, R.J.A., Belt, E., Bril, H., Stockmann, H.B.A.C., Hooijberg, E., Punt, C.J.A., Koopman, M., Nagtegaal, I.D., Coupé, V.H.M., Carvalho, B., Meijer, G.A.

“…Microsatellite instability (MSI) has been associated with favourable survival in early stage colorectal cancer (CRC) compared to microsatellite stable (MSS)…”
Get full text

Renal cancer and pneumothorax risk in Birt–Hogg–Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families by Houweling, A C, Gijezen, L M, Jonker, M A, van Doorn, M B A, Oldenburg, R A, van Spaendonck-Zwarts, K Y, Leter, E M, van Os, T A, van Grieken, N C T, Jaspars, E H, de Jong, M M, Bongers, E M H F, Johannesma, P C, Postmus, P E, van Moorselaar, R J A, van Waesberghe, J-Htm, Starink, T M, van Steensel, M A M, Gille, J J P, Menko, F H

“…Background: Birt–Hogg–Dubé (BHD) syndrome is an autosomal dominant condition caused by germline FLCN mutations, and characterised by fibrofolliculomas,…”
Get full text

pT4 stage II and III colon cancers carry the worst prognosis in a nationwide survival analysis. Shepherd's local peritoneal involvement revisited by Snaebjornsson, P., Coupe, V.M.H., Jonasson, L., Meijer, G.A., Grieken, N.C., Jonasson, J.G.

“…The aim of this study is to clarify the prognostic importance of several well‐known but still debated pathological variables related to the survival of colon…”
Get full text

Adjuvant chemotherapy for resected duodenal adenocarcinoma: a case-matched analysis in nation wide cohort by de Bakker, J. K., Meijer, L. L., Zonderhuis, B. M., van der Vliet, H. J., Daams, F., van Grieken, N. C. T., Lissenberg-Witte, B. I., Kazemier, G.

“…Duodenal adenocarcinoma (DA) is a rare tumor for which survival data on adjuvant chemotherapy in patients after surgical treatment are unclear. This…”
Get full text

Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial by Claassen, Y.H.M., Hartgrink, H.H., Dikken, J.L., de Steur, W.O., van Sandick, J.W., van Grieken, N.C.T., Cats, A., Trip, A.K., Jansen, E.P.M., Meershoek-Klein Kranenbarg, W.M., Braak, J.P.B.M., Putter, H., van Berge Henegouwen, M.I., Verheij, M., van de Velde, C.J.H.

“…In order to determine the optimal combination of perioperative chemotherapy and chemoradiotherapy for Western patients with advanced resectable gastric cancer,…”
Get full text

Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis by Creemers, A., ter Veer, E., de Waal, L., Lodder, P., Hooijer, G. K. J., van Grieken, N. C. T., Bijlsma, M. F., Meijer, S. L., van Oijen, M. G. H., van Laarhoven, H. W. M.

“…Trastuzumab combined with chemotherapy is standard of care for HER2 positive advanced gastro-esophageal cancers. The reported prevalence of HER2 discordance…”
Get full text

Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma by Goedegebuure, R.S.A., Harrasser, M., de Klerk, L.K., van Schooten, T.S., van Grieken, N.C.T., Eken, M., Grifhorst, M.S., Pocorni, N., Jordanova, E.S., van Berge Henegouwen, M.I., Pouw, R.E., Verheul, H.M.W., van der Vliet, J.J., van Laarhoven, H.W.M., Thijssen, V.L.J.L, Bass, A.J., De Gruijl, T.D., Derks, S.

“…Esophageal adenocarcinoma (EAC) is a disease with dismal treatment outcomes. Response to neoadjuvant chemoradiation (CRT) varies greatly. Although the…”
Get full text

MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing by Neerincx, M, Sie, D L S, van de Wiel, M A, van Grieken, N C T, Burggraaf, J D, Dekker, H, Eijk, P P, Ylstra, B, Verhoef, C, Meijer, G A, Buffart, T E, Verheul, H M W

“…MicroRNAs (miRs) have been recognized as promising biomarkers. It is unknown to what extent tumor-derived miRs are differentially expressed between primary…”
Get full text

Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial by Claassen, Y. H. M., Hartgrink, H. H., de Steur, W. O., Dikken, J. L., van Sandick, J. W., van Grieken, N. C. T., Cats, A., Trip, A. K., Jansen, E. P. M., Kranenbarg, W. M. Meershoek-Klein, Braak, J. P. B. M., Putter, H., van Berge Henegouwen, M. I., Verheij, M., van de Velde, C. J. H.

“…Background Preoperative randomization for postoperative treatment might affect quality of surgery. In the CRITICS trial (ChemoRadiotherapy after Induction…”
Get full text

Epidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in the Netherlands by de Vries, A C, Meijer, G A, Looman, C W N, Casparie, M K, Hansen, B E, van Grieken, N C T, Kuipers, E J

“…Background:The pre-malignant gastric lesions atrophic gastritis (AG), intestinal metaplasia (IM) and dysplasia (DYS) have long been identified as principal…”
Get full text

Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer by van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C. T., Dekker, H., van Dongen, G. A. M. S., Vugts, D. J., Boellaard, R., van Herpen, C. M. L., de Vries, E. G. E., Oyen, W. J. G., Brouwers, A. H., Verheul, H. M. W., Hoekstra, O. S., der Houven van Oordt, C. W. Menke-van

“…Missing Electronic Supplementary Materials…”
Get full text

MAL promoter hypermethylation as a novel prognostic marker in gastric cancer by Buffart, T E, Overmeer, R M, Steenbergen, R D M, Tijssen, M, van Grieken, N C T, Snijders, P J F, Grabsch, H I, van de Velde, C J H, Carvalho, B, Meijer, G A

“…T-lymphocyte maturation associated protein, MAL, has been described as a tumour-suppressor gene with diagnostic value in colorectal and oesophageal cancers,…”
Get full text